4886 — ASKA Pharmaceutical Holdings Co Income Statement

0.000.00%

Last trade - 00:00

Annual income statement for ASKA Pharmaceutical Holdings Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Tanshin
Standards:	JAS	JAS	JAS	JAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	56,607	60,461	62,843	64,139	71,127
Cost of Revenue
Gross Profit	26,352	28,585	30,665	31,336	34,145
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	59,954	55,353	56,343	57,851	65,441
Operating Profit	-3,347	5,108	6,500	6,288	5,686
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,163	5,357	9,862	6,192	6,991
Provision for Income Taxes
Net Income After Taxes	4,290	4,239	7,546	5,101	5,625
Minority Interest
Net Income Before Extraordinary Items
Net Income	4,290	4,239	7,546	5,101	5,425
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,290	4,238	7,545	5,101	5,424
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	121	152	267	155	201
Dividends per Share